New drug cevostamab enters early human testing for lupus

NCT ID NCT07629583

Recruiting now Disease control Sponsor: Genentech, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 07, 2026 · Updated 3 times

Summary

This early-stage trial will test the safety and tolerability of a new drug, cevostamab, in 46 people with systemic lupus erythematosus, some of whom also have active lupus nephritis. The drug is given intravenously, and researchers will monitor side effects and how the drug moves through the body. This is a first step to see if cevostamab might help control lupus.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Cevostamab
What this could lead to: If it works, this could point toward a new treatment option for lupus that targets the immune system more precisely.
What could go wrong: This is a very early Phase 1 trial with only 46 people, focused on safety and dosing. It may not lead to an effective treatment, and side effects like cytokine release syndrome are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LUPUS ERYTHEMATOSUS, SYSTEMIC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

lupus nephritis systemic lupus erythematosus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LUPUS ERYTHEMATOSUS, SYSTEMIC

Contacts and locations

Locations

Hospital Universitario Virgen Macarena
RECRUITING

Seville, 41009, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.